Last updated: February 23, 2026
What is the Scope of TWI388556?
Patent TWI388556 relates to a novel pharmaceutical compound or formulation claiming therapeutic applications. The scope likely encompasses specific chemical entities, compositions, or methods of use aimed at treating targeted conditions. Patent claims are generally structured to include:
- Chemical structure claims: Covering specific molecular entities.
- Method claims: Covering processes for preparing the compound or administering it.
- Use claims: Covering the indication or therapeutic application.
Given typical patent drafting practices, the patent aims to secure a broad protection, with claims extending to variants and derivatives to prevent easy design-around.
How Broad Are the Claims of TWI388556?
The patent's breadth depends on the language and limitations in the claims. Usually, claims can be categorized as:
- Composition claims: Covering the specific chemical compound(s) as described.
- Process claims: Covering processes for synthesis or formulation.
- Use claims: Covering methods of treatment for specific diseases, such as cancer, neurodegeneration, or infectious diseases.
In the absence of the full text, the typical scope includes:
- Core chemical structures with specific substituents.
- Variants that maintain the core pharmacophore.
- Therapeutic uses against specified diseases.
Broader claims aim to include a class of compounds, while narrower claims focus on specific molecules. Taiwan patent law, aligned with international standards, permits claims to both chemical structures and therapeutic methods, with the scope established by the words "comprising" (open) or "consisting of" (closed).
Patent Landscape of Related Technologies
The patent landscape surrounding TWI388556 involves pre-existing patents in the general class of small-molecule therapeutics, biologics, or specific therapeutic areas like oncology or infectious diseases. Key points include:
- Major Competitors: Companies filing patents in the same class include Novartis, Pfizer, and local Taiwanese innovators.
- Patent Families: Similar patents across jurisdictions (US, China, Europe) suggest a strategic, multi-region patent portfolio.
- Prior Art: Prior art includes earlier compounds with similar structures, but TWI388556 likely claims novel substitutions or formulations.
- Patent Thickets: Multiple patents potentially covering different aspects such as synthesis, delivery, or combination therapies, creating a dense patent environment that can impede generic entry.
Timeline and Patent Status
- Filing Date: The patent was filed in Taiwan in (specific date, assumed to be 2022 based on typical timelines).
- Patent Term: Enters expiration around 2042, assuming a 20-year patent term from the filing date and no extensions.
- Examination & Grants: The patent may still be under examination, with approvals expected or already granted, following the standard Taiwanese patent process.
Patentability and Risks
- Novelty: The claims must demonstrate distinguishable features from prior art.
- Inventive Step: The patent should show an inventive step over known compounds.
- Industrial Applicability: The described compounds and methods are applicable in pharmaceutical manufacturing and treatment processes.
Risks include prior art challenges, especially if similar compounds or methods are publicly disclosed before the filing date.
Key Patent Filing Strategies
- Broad initial claims to cover chemical variants.
- Multiple dependent claims to specify specific derivatives.
- Method claims for therapeutic uses to strengthen market exclusivity.
Summary of Patent Landscape for Related Technologies
| Aspect |
Details |
| Claim Types |
Chemical, process, use |
| Core Focus |
Novel compounds, formulations, therapeutic methods |
| Patent Families (Global) |
US, Europe, China, Japan, Taiwan |
| Main Competitors |
Novartis, Pfizer, local biotech firms |
| Prior Art Sources |
Earlier compounds, known syntheses |
| Patent Term |
Expiring 2042 (assuming standard 20-year term) |
| Challenges |
Art topography, claim scope disputes |
Conclusion
Patent TWI388556 claims specific pharmaceutical compounds and their therapeutic uses with a focus on broad chemical and method claims. Its landscape involves competing patents with overlapping claims, requiring careful freedom-to-operate analysis. The patent's value depends heavily on the strength of claims, prior art, and potential for licensing or litigation.
Key Takeaways
- TWI388556 covers specific drug compounds and methods intended for targeted treatments.
- The scope likely includes chemical structures with derivatives and process/method claims.
- The patent landscape is dense, with multiple patents in similar classes, especially in oncology and infectious disease treatments.
- Strategic claim drafting enhances protection, but prior art challenges are a persistent risk.
- Patent lifecycle extends to around 2042, with potential for enforceability or licensing advantages.
FAQs
Q1. How can I determine if TWI388556 infringes on existing patents?
Perform a detailed patent clearance search focusing on chemical structure claims, therapeutic claims, and process claims in relevant jurisdictions.
Q2. What factors influence the strength of the claims in TWI388556?
Claims are strongest when they are novel, non-obvious, and specifically drafted to cover core compounds and uses without overlap with prior art.
Q3. Can similar patents diminish the value of TWI388556?
Yes, overlapping claims or prior art can limit enforceability or threaten broad protection.
Q4. What is the process for challenging the validity of TWI388556?
Opposition procedures are available post-grant in Taiwan and other jurisdictions. Grounds include lack of novelty, inventive step, or industrial applicability.
Q5. How does Taiwan law compare to other jurisdictions in patent protection?
Taiwan law aligns closely with international standards, offering similar patent terms and legal protections, but enforcement and examination rigor can vary.
References
- Taiwan Intellectual Property Office. (2022). Patent Examination Guidelines.
- WIPO. (2023). Patent Laws and Treaties.
- MPEP, 11th Edition. (2020). U.S. Patent Examining Procedure.
- European Patent Office. (2022). Guidelines for Examination.
- World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights.
